Table 1.
Summary of patients’ characteristics
| cFiO2 <0.5 | cFiO2 ≥0.5 | ||
|---|---|---|---|
| n = 156 | n = 43 | P | |
| Preoperative recipient factors | |||
| Age, year* | 54 (46–61) | 53 (39–61) | 0.737 |
| Sex (male/female) | 80/76 | 22/21 | 1.000 |
| Hospitalized or ICU, n (%) | 84 (54) | 26 (60) | 0.491 |
| Positive 3 body composition markers, n (%) | 7 (5) | 1 (2) | 1.000 |
| Etiology | 0.324 | ||
| HBV/HCV, n (%) | 67 (43) | 13 (30) | |
| AIH/PBC/PSC, n (%) | 29 (19) | 7 (16) | |
| Biliary atresia, n (%) | 13 (8) | 4 (9) | |
| Other, n (%) | 47 (30) | 19 (44) | |
| Hepatocellular carcinoma, n (%) | 49 (31) | 11 (26) | 0.574 |
| Fulminant hepatic failure, n (%) | 5 (3) | 3 (7) | 0.375 |
| MELD score* | 17 (13–20) | 17 (13–27) | 0.468 |
| Hepatorenal syndrome, n (%) | 11 (7) | 6 (14) | 0.213 |
| Respiratory function | |||
| %VC, %* | 92 (78–104) | 86 (69–103) | 0.308 |
| FEV1/FVC ratio, %* | 83.1 (78.7–87.6) | 83.4 (77.4–88.7) | 0.760 |
| Results of blood test | |||
| AST, IU/L* | 53 (33–87) | 41 (27–67) | 0.052 |
| ALT, IU/L* | 32 (19–53) | 23 (17–35) | 0.023† |
| Albumin, g/dL* | 3.0 (2.4–3.2) | 3.0 (2.4–3.2) | 0.627 |
| Total bilirubin, mg/dL* | 3.9 (2.0–8.3) | 3.3 (1.6–14.9) | 0.814 |
| Creatinine, mg/dL* | 0.7 (0.6–0.9) | 0.7 (0.6–0.9) | 0.996 |
| PT-INR* | 1.5 (1.3–1.8) | 1.6 (1.3–1.9) | 0.440 |
| White blood cell count, × 1000/m3* | 3.7 (2.5–5.2) | 3.9 (2.7–5.9) | 0.582 |
| Hemoglobin, g/dL* | 9.6 (8.5–11.5) | 9.2 (8.1–10.9) | 0.222 |
| Platelet count, × 1000/μL* | 64 (39–101) | 66 (37–99) | 0.904 |
| Donor factors | |||
| Age, year* | 45 (31–56) | 45 (34–56) | 0.794 |
| GRWR, %* | 0.9 (0.7–1.1) | 0.8 (0.7–1.0) | 0.142 |
| Blood type incompatible donor, n (%) | 35 (22) | 15 (34) | 0.113 |
| Graft type, left/right lobe graft | 73/83 | 21/22 | 0.864 |
| Intraoperative parameters | |||
| Operation time, hour* | 14 (12–16) | 15 (12–18) | 0.421 |
| Blood loss, L* | 5.7 (3.5–10.2) | 6.8 (3.0–17.0) | 0.326 |
| Cold ischemia time, hour* | 1.8 (1.0–2.8) | 2.2 (1.1–3.6) | 0.178 |
| Warm ischemia time, min* | 44 (37–54) | 39 (33–50) | 0.012† |
| PVP before abdominal closure, mmHg* | 12 (10–14) | 13 (11–14) | 0.110 |
| Intraoperative splenectomy, n (%) | 65 (42) | 13 (30) | 0.217 |
| Total volume of infusion, L* | 13.4 (9.9–18.3) | 14.8 (8.9–29.4) | 0.260 |
| Postoperative parameters | |||
| In-hospital mortality, n (%) | 20 (13) | 8 (19) | 0.330 |
| Positive blood culture, n (%) | 49 (31) | 20 (47) | 0.072 |
| Reoperation, n (%) | 29 (19) | 14 (33) | 0.060 |
| Acute cellular or humoral rejection, n (%) | 90 (58) | 25 (58) | 1.000 |
| EAD, n (%) | 50 (32) | 21 (49) | 0.049 |
| Causes of graft loss | 0.684 | ||
| Liver failure, n (%) | 12 (35) | 7 (44) | |
| Multiple organ failure, n (%) | 7 (21) | 2 (13) | |
| Sepsis, n (%) | 10 (29) | 3 (19) | |
| ARDS, n (%) | 1 (3) | 0 (0) | |
| Other, n (%) | 4 (12) | 4 (25) | |
*Data are presented as the median and interquartile range. Calculated FiO2 (cFiO2) was defined as {O2(L) + Air(L) × 0.21}/{O2(L) + Air(L)}. †P <0.05
AIH autoimmune hepatitis; ALT alanine aminotransferase; ARDS acute respiratory distress syndrome; AST aspartate aminotransferase; EAD early allograft dysfunction; FEV1/FVC forced expiratory volume in one second/forced vital capacity; FiO2 fraction of inspiratory oxygen; GRWR graft-to-recipient weight ratio; HBV hepatitis B virus; HCV hepatitis C virus; ICU intensive care unit; MELD model for end-stage liver disease; PBC primary biliary cholangitis; PSC primary sclerosing cholangitis; PT-INR prothrombin time–international normalized ratio; PVP portal vein pressure; %VC percent vital capacity